Therefore, we examined the ability of systemic or local CLL administration, or DT treatment, to deplete CD169+ SCS macrophages or SIGN-R1+ medullary macrophages by microscopy. Here, SIGLEC1 is linked to B-cell chronic lymphocytic leukemia.